RxDoctor Payments Data

William Crosland, MD

Interventional Cardiology · Savannah, GANPI 1518102219

Payments from drug & device makers

$4,055in general payments, 2019–2025

Across 127 payments — averaging $31.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$588
  • Cvrx, Inc.$488
  • Inari Medical, Inc.$410
  • Novartis$333
  • Abbott$304
  • Abiomed$284
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,055 in reported general payments places this provider in the 25th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$204,072
Medicare patients
785
Services billed
2,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$286,878
EntrestoSacubitril/Valsartan156$129,079
XareltoRivaroxaban40$31,665
FarxigaDapagliflozin Propanediol44$30,697
Repatha SureclickEvolocumab12$9,749
Metoprolol Succinate736$7,696
Carvedilol301$2,055
Atorvastatin Calcium236$1,566
Losartan Potassium225$1,309
Flecainide Acetate31$1,258
Furosemide350$1,225
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$1,217
Ranolazine ErRanolazine17$1,197
Valsartan25$993
Diltiazem 24hr Er (La)Diltiazem Hcl12$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$286,878346 claims
NovartisEntresto$333$129,079156 claims
Johnson & JohnsonXarelto$39$31,66540 claims
AstraZenecaFarxiga$118$30,69744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →